Published Papers & Misc - SHIMIZU Masaki

Division display  161 - 180 of about 271 ／  All the affair displays >>

  1. Kubota T, Takei S, Shimizu M, Yasumura J, Nakagishi Y, Kizawa T, Yashiro M, Wakiguchi H, Yamasaki Y, Kawano Y. Early prediction for over two years efficacy of the first biologic agent for polyarticular juvenile idiopathic arthritis: A multi-institutional study in Japan. Modern rheumatology. 2018.09; 28 (5): 826-831. ( PubMed, DOI )

  2. Okamoto Nami, Shabana Kosuke, Nakagishi Yasuo, Nishimura Kenichi, Mizuta Mao, Okura Yuka, Shimizu Masaki, Wakiguchi Hiroyuki, Yasumura Junko, Mori Masaaki. Methotrexate Polyglutamates As an Evaluation Tool for Appropriate Dosage of Oral Methotrexate Administration in Pediatric Patients ARTHRITIS & RHEUMATOLOGY. 2018.09; 70

  3. Shimizu Masaki, Mizuta Mao, Yasumi Takahiro, Iwata Naomi, Okura Yuka, Kinjo Noriko, Umebayashi Hiroaki, Kubota Tomohiro, Nakagishi Yasuo, Nishimura Kenichi, Yashiro Masato, Yasumura Junko, Yamazaki Kazuko, Wakiguchi Hiroyuki, Okamoto Name, Mori Masaaki. Validation of Classification Criteria of Macrophage Activation Syndrome in Japanese Patients With Systemic Juvenile Idiopathic Arthritis ARTHRITIS CARE & RESEARCH. 2018.09; 70 (9): 1412-1415. ( PubMed, DOI )

  4. Kubota Tomohiro, Takei Syuji, Shimizu Masaki, Yasumura Junko, Nakagishi Yasuo, Kizawa Toshitaka, Yashiro Masato, Wakiguchi Hiroyuki, Yamasaki Yuichi, Kawano Yoshifumi. 多関節型若年性特発性関節炎に対して初回導入した生物学的製剤の2年以上の有効性に関する早期予測　日本における多施設共同研究(Early prediction for over two years efficacy of the first biologic agent for polyarticular juvenile idiopathic arthritis: A multi-institutional study in Japan) Modern Rheumatology. 2018.09; 28 (5): 826-831. ( ichushi )

  5. Shimizu M, Mizuta M, Usami M, Inoue N, Sakakibara Y, Yamada K, Konishi M, Ohta K, Yachie A. Clinical significance of serum soluble TNF receptor II level and soluble TNF receptor II/I ratio as indicators of coronary artery lesion development in Kawasaki disease. Cytokine. 2018.08; 108 168-172. ( PubMed, DOI )

  6. Takakura M, Shimizu M, Mizuta M, Inoue N, Tasaki Y, Ohta K, Furuichi K, Wada T, Yachie A. Successful treatment of rituximab- and steroid-resistant nephrotic syndrome with leukocytapheresis. Journal of clinical apheresis. 2018.06; 33 (3): 409-411. ( PubMed, DOI )

  7. Schulert GS, Minoia F, Bohnsack J, Cron RQ, Hashad S, KonÉ-Paut I, Kostik M, Lovell D, Maritsi D, Nigrovic PA, Pal P, Ravelli A, Shimizu M, Stanevicha V, Vastert S, Woerner A, de Benedetti F, Grom AA. Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. Arthritis care & research. 2018.03; 70 (3): 409-419. ( PubMed, DOI )

  8. Kinjo N, Hamada K, Hirayama C, Shimizu M. Role of plasma exchange, leukocytapheresis, and plasma diafiltration in management of refractory macrophage activation syndrome. Journal of clinical apheresis. 2018.02; 33 (1): 117-120. ( PubMed, DOI )

  9. Tasaki Y, Shimizu M, Takarkura M, Ohta K, Yachie A. Urinary aquaporin-2 as a possible objective biomarker of nocturnal polyuria. Pediatrics international : official journal of the Japan Pediatric Society. 2018.02; 60 (2): 192-194. ( PubMed, DOI )

  10. Tasaki Yuko, Shimizu Masaki, Takarkura Maiko, Ohta Kazuhide, Yachie Akihiro. 夜間多尿の客観的バイオマーカーになり得る尿中aquaporin-2(Urinary aquaporin-2 as a possible objective biomarker of nocturnal polyuria) Pediatrics International. 2018.02; 60 (2): 192-194. ( ichushi )

  11. Niida Y, Ozaki M, Shimizu M, Ueno K, Tanaka T. Classification of Uniparental Isodisomy Patterns That Cause Autosomal Recessive Disorders: Proposed Mechanisms of Different Proportions and Parental Origin in Each Pattern. Cytogenetic and genome research. 2018; 154 (3): 137-146. ( PubMed, DOI )

  12. Mizuta M, Shimizu M, Nakagishi Y, Kasai K, Yachie A. Bicipital synovial cyst associated with systemic juvenile idiopathic arthritis: new insights obtained from unique pathological findings. International journal of rheumatic diseases. 2017.12; 20 (12): 2242-2244. ( PubMed, DOI )

  13. Shimizu Masaki, Inoue Natsumi, Kuroda Mondo, Irabu Hitoshi, Takakura Maiko, Kaneda Hisashi, Sugimoto Naotoshi, Ohta Kazuhide, Yachie Akihiro. 腸管出血性大腸菌誘発性の溶血性尿毒症症候群における脳障害発症の指標としての血清フェリチン(Serum ferritin as an indicator of the development of encephalopathy in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome) Clinical and Experimental Nephrology. 2017.12; 21 (6): 1083-1087. ( ichushi )

  14. Shimizu M, Inoue N, Kuroda M, Irabu H, Takakura M, Kaneda H, Sugimoto N, Ohta K, Yachie A. Serum ferritin as an indicator of the development of encephalopathy in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Clinical and experimental nephrology. 2017.12; 21 (6): 1083-1087. ( PubMed, DOI )

  15. Yasumura Junko, Yashiro Masato, Okamoto Nami, Shabana Kosuke, Umebayashi Hiroaki, Iwata Naomi, Kubota Tomohiro, Mizuta Mao, Nishimura Kenichi, Okura Yuka, Shimizu Masaki, Tomiita Minako, Takei Syuji, Mori Masaaki. Clinical Features and Characteristics of Juvenile Idiopathic Arthritis-Associated Uveitis in Japan: the First Report from the Pediatric Rheumatology Association of Japan (PRAJ) ARTHRITIS & RHEUMATOLOGY. 2017.10; 69

  16. Nagai T, Uemura O, Kaneda H, Ushijima K, Ohta K, Gotoh Y, Satomura K, Shimizu M, Fujieda M, Morooka M, Yamada T, Yamada M, Wada N, Hashimoto Y. The true distribution volume and bioavailability of mizoribine in children with chronic kidney disease. Clinical and experimental nephrology. 2017.10; 21 (5): 884-888. ( PubMed, DOI )

  17. Shimizu Masaki, Mizuta Mao, Yasumi Takahiro, Iwata Naomi, Okura Yuka, Kinjo Noriko, Umebayashi Hiroaki, Kubota Tomohiro, Nakagishi Yasuo, Nishimura Kenichi, Yashiro Masato, Yasumura Junko, Yamazaki Kazuko, Wakiguchi Hiroyuki, Okamoto Nami, Mori Masaaki. Validation of 2016 ACR/EULAR Classification Criteria of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis in Japanese Patients ARTHRITIS & RHEUMATOLOGY. 2017.10; 69

  18. Nagai Takuhito, Uemura Osamu, Kaneda Hisashi, Ushijima Katsumi, Ohta Kazuhide, Gotoh Yoshimitsu, Satomura Kenichi, Shimizu Masaki, Fujieda Mikiya, Morooka Masashi, Yamada Takuji, Yamada Masayoshi, Wada Naohiro, Hashimoto Yukiya. 慢性腎臓病を有する小児におけるミゾリビンの真の分布容積およびバイオアベイラビリティ(The true distribution volume and bioavailability of mizoribine in children with chronic kidney disease) Clinical and Experimental Nephrology. 2017.10; 21 (5): 884-888. ( ichushi )

  19. Shimizu M, Nakagishi Y, Inoue N, Mizuta M, Yachie A. Leucine-rich α2-glycoprotein as the acute-phase reactant to detect systemic juvenile idiopathic arthritis disease activity during anti-interleukin-6 blockade therapy: A case series. Modern rheumatology. 2017.09; 27 (5): 833-837. ( PubMed, DOI )

  20. Shimizu Masaki, Nakagishi Yasuo, Inoue Natsumi, Mizuta Mao, Yachie Akihiro. 抗インターロイキン-6遮断療法中の全身性若年性特発性関節炎疾患活動性を検出するための急性相反応物質としてのleucine-rich α2-glycoprotein　症例シリーズ(Leucine-rich α2-glycoprotein as the acute-phase reactant to detect systemic juvenile idiopathic arthritis disease activity during anti-interleukin-6 blockade therapy: A case series) Modern Rheumatology. 2017.09; 27 (5): 833-837. ( ichushi )

< PREV - NEXT >

To the head of this page.▲